
2. The compound or salt according to claim 1, wherein $R^{1'}$ is
(1) a morpholinyl group optionally substituted by C_{1-6} alkyl group(s),
(2) a piperidyl group substituted by C_{1-6} alkyl group(s),
(3) a pyrrolidinyl group substituted by C_{1-6} alkyl group(s) optionally substituted by C_{1-6} alkoxy group(s),
(4) a pyrrolyl group substituted by C_{1-6} alkyl group(s),
(5) an imidazolyl group substituted by C_{1-6} alkyl group(s),
(6) an amino group optionally substituted by 1 or 2 substituents selected from
(a) a C_{1-6} alkyl group optionally substituted by substituent(s) selected from a C_{3-6} cycloalkyl group and a phenyl group, and
(b) a C_{3-6} cycloalkyl group,
(7) a C_{1-6} alkylsulfanyl group,
(8) a C_{1-6} alkoxy group optionally substituted by C_{3-6} cycloalkyl group(s),
(9) a C_{3-6} cycloalkyl group, or
(10) a C_{3-6} cycloalkenyl group.

3. A compound represented by the formula (I)



(I)

wherein
R^1 is a morpholino group optionally substituted by C_{1-6} alkyl group(s), a di(C_{1-6} alkyl)amino group, a C_{1-6} alkoxy group optionally substituted by C_{3-6} cycloalkyl group(s), a C_{3-6} cycloalkyl group or a C_{3-6} cycloalkenyl group; and
R^2 is a hydrogen atom or a C_{1-6} alkyl group,
or a salt thereof.

4. The compound or salt according to claim 3, wherein R^1 is a

morpholino group optionally substituted by C_{1-6} alkyl group(s), a di(C_{1-6} alkyl)amino group, a C_{1-6} alkoxy group or a C_{3-6} cycloalkyl group.~~,~~
~~or a salt thereof.~~

5. The compound or salt according to claim 3, wherein R^1 is a morpholino group optionally substituted by substituent(s) selected from a methyl group and an ethyl group, an N-methyl-N-(1-methylethyl)amino group, an isopropoxy group or a cyclopropyl group; and
R^2 is a hydrogen atom or a methyl group.~~,~~
~~or a salt thereof.~~

6. 3-(1-Methylethoxy)-6,7,8,9-tetrahydropyrazino[2,3-f][1,4]oxazepine or a salt thereof.

7. 3-(3-Methylmorpholin-4-yl)-6,7,8,9-tetrahydropyrazino[2,3-f][1,4]oxazepine or a salt thereof.

8. 6-Methyl-3-(morpholin-4-yl)-6,7,8,9-tetrahydropyrazino[2,3-f][1,4]oxazepine or a salt thereof.

9. 6-Methyl-3-(3-methylmorpholin-4-yl)-6,7,8,9-tetrahydropyrazino[2,3-f][1,4]oxazepine or a salt thereof.

10. N-Methyl-N-(1-methylethyl)-6,7,8,9-tetrahydropyrazino[2,3-f][1,4]oxazepin-3-amine or a salt thereof.

11. 3-(3-Ethylmorpholin-4-yl)-6,7,8,9-tetrahydropyrazino[2,3-f][1,4]oxazepine or a salt thereof.

12. 3-Cyclopropyl-6,7,8,9-tetrahydropyrazino[2,3-f][1,4]oxazepine or a salt thereof.

13. 3-(2-Methylpiperidin-1-yl)-6,7,8,9-tetrahydropyrazino[2,3-

f][1,4]oxazepine or a salt thereof.

14. 3-(2-Methylpyrrolidin-1-yl)-6,7,8,9-tetrahydropyrazino[2,3-f][1,4]oxazepine or a salt thereof.

15. A medicament comprising the compound or salt of any one of claims 1-14~~, or a salt thereof~~.

16. The medicament according to claim 15, which is a serotonin 5-HT_{2C} receptor activator.

17. The medicament according to claim 15, which is a drug for the prophylaxis or treatment of a lower urinary tract symptom, obesity, and/or organ prolapse.

18. Use of the compound or salt of any one of claims 1-14, ~~or a salt thereof,~~ for the production of a drug for the prophylaxis or treatment of a lower urinary tract symptom, obesity and/or organ prolapse.